Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for UCBJF and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for UCBJF and 80,000+ other tickers.
See exactly how UCBJF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for UCBJF and 80,000+ other tickers.
UCB S.A. is a prominent biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for individuals affected by neurological and immunological disorders. Its extensive portfolio of marketed products includes Cimzia, indicated for various inflammatory TNF-mediated diseases such as Crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, and axial spondyloarthritis (both radiographic and non-radiographic forms). For epilepsy management, UCB provides Vimpat, Keppra, and Briviact, alongside Nayzilam…
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does United Community Banks (UCB) have what it takes?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does United Community Banks (UCB) have what it takes?
UCB SA (UCBJY) Q2 2026 Earnings Call Transcript
Belgian biopharmaceutical group UCB raised its 2026 earnings guidance on Thursday, but its shares fell more than 8% as investors focused on weaker-than-expected sales of flagship drug Bimzelx and questioned the quality of the earnings upgrade.
United Community Banks, Inc. (UCB) Q2 2026 Earnings Call Transcript